RATIONALE: In rats, neurotoxic doses of methamphetamine (MA) induce astrogliosis, long lasting monoamine reductions, reuptake transporter down-regulation, and learning impairments. OBJECTIVE: We tested whether comparable effects occur in C57BL/6 mice. METHOD: C57BL/6 mice were treated with 10mg/kgs.c.x4 MA on a single day and evaluated at various intervals thereafter. RESULTS: The neurotoxic dose regimen of MA caused the predicted acute hyperthermia and increased striatal glial fibrillary acidic protein and reduced neostriatal dopamine. The MA-treated mice were hypoactive 24h later but not 48h later. MA-treated mice also showed exaggerated initial hyperactivity after a pharmacological dose of MA used to stimulate locomotion followed by a later phase of hypoactivity compared to saline-treated mice. No differences were observed on learning or memory tests (novel object recognition, egocentric, or spatial learning/memory). MA-treated mice showed a trend toward increased prepulse inhibition but not baseline acoustic startle reactivity. After testing, MA-treated mice showed reduced neostriatal dopamine and increased basal plasma corticosterone. CONCLUSIONS: A neurotoxic/binge regimen of MA in mice that produces the typical pattern of neurotoxic changes to those seen in rats, results in few behavioral changes. This may limit the utility of C57BL/6 mice for modeling the cognitive and behavioral effects described in human MA users who show such changes even after prolonged abstinence.
RATIONALE: In rats, neurotoxic doses of methamphetamine (MA) induce astrogliosis, long lasting monoamine reductions, reuptake transporter down-regulation, and learning impairments. OBJECTIVE: We tested whether comparable effects occur in C57BL/6 mice. METHOD: C57BL/6 mice were treated with 10mg/kgs.c.x4 MA on a single day and evaluated at various intervals thereafter. RESULTS: The neurotoxic dose regimen of MA caused the predicted acute hyperthermia and increased striatal glial fibrillary acidic protein and reduced neostriatal dopamine. The MA-treated mice were hypoactive 24h later but not 48h later. MA-treated mice also showed exaggerated initial hyperactivity after a pharmacological dose of MA used to stimulate locomotion followed by a later phase of hypoactivity compared to saline-treated mice. No differences were observed on learning or memory tests (novel object recognition, egocentric, or spatial learning/memory). MA-treated mice showed a trend toward increased prepulse inhibition but not baseline acoustic startle reactivity. After testing, MA-treated mice showed reduced neostriatal dopamine and increased basal plasma corticosterone. CONCLUSIONS: A neurotoxic/binge regimen of MA in mice that produces the typical pattern of neurotoxic changes to those seen in rats, results in few behavioral changes. This may limit the utility of C57BL/6 mice for modeling the cognitive and behavioral effects described in human MA users who show such changes even after prolonged abstinence.
Authors: Una D McCann; Hiroto Kuwabara; Anil Kumar; Michael Palermo; Rubyna Abbey; James Brasic; Weiguo Ye; Mohab Alexander; Robert F Dannals; Dean F Wong; George A Ricaurte Journal: Synapse Date: 2008-02 Impact factor: 2.562
Authors: Nicole R Herring; Tori L Schaefer; Gary A Gudelsky; Charles V Vorhees; Michael T Williams Journal: Psychopharmacology (Berl) Date: 2008-05-29 Impact factor: 4.530
Authors: Annabelle M Belcher; Erin M Feinstein; Steven J O'Dell; John F Marshall Journal: Neuropsychopharmacology Date: 2007-07-18 Impact factor: 7.853
Authors: W E Fantegrossi; J R Ciullo; K T Wakabayashi; R De La Garza; J R Traynor; J H Woods Journal: Neuroscience Date: 2007-11-17 Impact factor: 3.590
Authors: Daniel Alvarez-Fischer; Carmen Henze; Corinna Strenzke; Jan Westrich; Boris Ferger; Günter U Höglinger; Wolfgang H Oertel; Andreas Hartmann Journal: Exp Neurol Date: 2007-11-01 Impact factor: 5.330
Authors: Nicole R Herring; Tori L Schaefer; Peter H Tang; Matthew R Skelton; James P Lucot; Gary A Gudelsky; Charles V Vorhees; Michael T Williams Journal: BMC Neurosci Date: 2008-05-30 Impact factor: 3.288
Authors: Nicholas B Miner; Josh S Elmore; Michael H Baumann; Tamara J Phillips; Aaron Janowsky Journal: Neurotoxicology Date: 2017-09-15 Impact factor: 4.294
Authors: Sarah E A McConnell; M Kerry O'Banion; Deborah A Cory-Slechta; John A Olschowka; Lisa A Opanashuk Journal: Neurotoxicology Date: 2015-08-15 Impact factor: 4.294
Authors: Brook L Henry; Mark A Geyer; Mahalah Buell; William Perry; Jared W Young; Arpi Minassian Journal: Behav Brain Res Date: 2012-08-31 Impact factor: 3.332